Canakinumab's Effect Against Subsequent Gout Flares and High‐Sensitivity C‐Reactive Protein Levels: A Causal Mediation Analysis

The objective of this study was to quantify the value of early suppression of high‐sensitivity C‐reactive protein (hsCRP) levels as a biomarker of the protective role of canakinumab against future gout flares.

[1]  B. Whitcomb,et al.  Defining, quantifying, and interpreting 'noncollapsibility' in epidemiologic studies of measures of "effect". , 2020, American journal of epidemiology.

[2]  Maya B. Mathur,et al.  Conducting Regression-based Causal Mediation Analysis Using the R Package "regmedint" , 2020 .

[3]  N. Dalbeth,et al.  Cost‐Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol , 2020, Arthritis care & research.

[4]  P. Libby,et al.  Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. , 2020, European heart journal.

[5]  R. Diaz,et al.  Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) , 2020, European heart journal. Quality of care & clinical outcomes.

[6]  L. Joosten,et al.  Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout , 2019, Annals of the rheumatic diseases.

[7]  N. Schlesinger.  Relationship of Interleukin-1 Blockade With Incident Gout and Serum Uric Acid Levels , 2019, Annals of Internal Medicine.

[8]  J. Singh,et al.  Brief Report: Validation of a Definition of Flare in Patients With Established Gout , 2018, Arthritis & rheumatology.

[9]  P. Libby,et al.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.

[10]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[11]  M. Pereira,et al.  Cytokine Profile in Gout: Inflammation Driven by IL-6 and IL-18? , 2016, Immunological investigations.

[12]  P. Ridker.  From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. , 2016, Circulation research.

[13]  H. Keen,et al.  Imaging in gout: A review of the recent developments , 2014, Therapeutic advances in musculoskeletal disease.

[14]  Linda Valeri,et al.  Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. , 2013, Psychological methods.

[15]  H. Schumacher,et al.  Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions , 2012, Annals of the rheumatic diseases.

[16]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[17]  A. So,et al.  Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study , 2011, Arthritis Research & Therapy.

[18]  Stijn Vansteelandt,et al.  Odds ratios for mediation analysis for a dichotomous outcome. , 2010, American journal of epidemiology.

[19]  A. So,et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.

[20]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[21]  T. VanderWeele,et al.  Mediation Formulas with Binary Mediators and Outcomes and the "Rare Outcome Assumption". , 2018, American journal of epidemiology.

[22]  J. Böhnke.  Explanation in causal inference: Methods for mediation and interaction. , 2016, Quarterly journal of experimental psychology.

[23]  Tyler J VanderWeele,et al.  eAppendix for : ” SAS macro for causal mediation analysis with survival data ” , 2014 .